Cargando…

Role for miR-204 in human pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is characterized by enhanced proliferation and reduced apoptosis of pulmonary artery smooth muscle cells (PASMCs). Because microRNAs have been recently implicated in the regulation of cell proliferation and apoptosis, we hypothesized that these regulatory molecu...

Descripción completa

Detalles Bibliográficos
Autores principales: Courboulin, Audrey, Paulin, Roxane, Giguère, Nellie J., Saksouk, Nehmé, Perreault, Tanya, Meloche, Jolyane, Paquet, Eric R., Biardel, Sabrina, Provencher, Steeve, Côté, Jacques, Simard, Martin J., Bonnet, Sébastien
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058572/
https://www.ncbi.nlm.nih.gov/pubmed/21321078
http://dx.doi.org/10.1084/jem.20101812
_version_ 1782200373659828224
author Courboulin, Audrey
Paulin, Roxane
Giguère, Nellie J.
Saksouk, Nehmé
Perreault, Tanya
Meloche, Jolyane
Paquet, Eric R.
Biardel, Sabrina
Provencher, Steeve
Côté, Jacques
Simard, Martin J.
Bonnet, Sébastien
author_facet Courboulin, Audrey
Paulin, Roxane
Giguère, Nellie J.
Saksouk, Nehmé
Perreault, Tanya
Meloche, Jolyane
Paquet, Eric R.
Biardel, Sabrina
Provencher, Steeve
Côté, Jacques
Simard, Martin J.
Bonnet, Sébastien
author_sort Courboulin, Audrey
collection PubMed
description Pulmonary arterial hypertension (PAH) is characterized by enhanced proliferation and reduced apoptosis of pulmonary artery smooth muscle cells (PASMCs). Because microRNAs have been recently implicated in the regulation of cell proliferation and apoptosis, we hypothesized that these regulatory molecules might be implicated in the etiology of PAH. In this study, we show that miR-204 expression in PASMCs is down-regulated in both human and rodent PAH. miR-204 down-regulation correlates with PAH severity and accounts for the proliferative and antiapoptotic phenotypes of PAH-PASMCs. STAT3 activation suppresses miR-204 expression, and miR-204 directly targets SHP2 expression, thereby SHP2 up-regulation, by miR-204 down-regulation, activates the Src kinase and nuclear factor of activated T cells (NFAT). STAT3 also directly induces NFATc2 expression. NFAT and SHP2 were needed to sustain PAH-PASMC proliferation and resistance to apoptosis. Finally, delivery of synthetic miR-204 to the lungs of animals with PAH significantly reduced disease severity. This study uncovers a new regulatory pathway involving miR-204 that is critical to the etiology of PAH and indicates that reestablishing miR-204 expression should be explored as a potential new therapy for this disease.
format Text
id pubmed-3058572
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-30585722011-09-14 Role for miR-204 in human pulmonary arterial hypertension Courboulin, Audrey Paulin, Roxane Giguère, Nellie J. Saksouk, Nehmé Perreault, Tanya Meloche, Jolyane Paquet, Eric R. Biardel, Sabrina Provencher, Steeve Côté, Jacques Simard, Martin J. Bonnet, Sébastien J Exp Med Article Pulmonary arterial hypertension (PAH) is characterized by enhanced proliferation and reduced apoptosis of pulmonary artery smooth muscle cells (PASMCs). Because microRNAs have been recently implicated in the regulation of cell proliferation and apoptosis, we hypothesized that these regulatory molecules might be implicated in the etiology of PAH. In this study, we show that miR-204 expression in PASMCs is down-regulated in both human and rodent PAH. miR-204 down-regulation correlates with PAH severity and accounts for the proliferative and antiapoptotic phenotypes of PAH-PASMCs. STAT3 activation suppresses miR-204 expression, and miR-204 directly targets SHP2 expression, thereby SHP2 up-regulation, by miR-204 down-regulation, activates the Src kinase and nuclear factor of activated T cells (NFAT). STAT3 also directly induces NFATc2 expression. NFAT and SHP2 were needed to sustain PAH-PASMC proliferation and resistance to apoptosis. Finally, delivery of synthetic miR-204 to the lungs of animals with PAH significantly reduced disease severity. This study uncovers a new regulatory pathway involving miR-204 that is critical to the etiology of PAH and indicates that reestablishing miR-204 expression should be explored as a potential new therapy for this disease. The Rockefeller University Press 2011-03-14 /pmc/articles/PMC3058572/ /pubmed/21321078 http://dx.doi.org/10.1084/jem.20101812 Text en © 2011 Courboulin et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
spellingShingle Article
Courboulin, Audrey
Paulin, Roxane
Giguère, Nellie J.
Saksouk, Nehmé
Perreault, Tanya
Meloche, Jolyane
Paquet, Eric R.
Biardel, Sabrina
Provencher, Steeve
Côté, Jacques
Simard, Martin J.
Bonnet, Sébastien
Role for miR-204 in human pulmonary arterial hypertension
title Role for miR-204 in human pulmonary arterial hypertension
title_full Role for miR-204 in human pulmonary arterial hypertension
title_fullStr Role for miR-204 in human pulmonary arterial hypertension
title_full_unstemmed Role for miR-204 in human pulmonary arterial hypertension
title_short Role for miR-204 in human pulmonary arterial hypertension
title_sort role for mir-204 in human pulmonary arterial hypertension
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058572/
https://www.ncbi.nlm.nih.gov/pubmed/21321078
http://dx.doi.org/10.1084/jem.20101812
work_keys_str_mv AT courboulinaudrey roleformir204inhumanpulmonaryarterialhypertension
AT paulinroxane roleformir204inhumanpulmonaryarterialhypertension
AT giguerenelliej roleformir204inhumanpulmonaryarterialhypertension
AT saksouknehme roleformir204inhumanpulmonaryarterialhypertension
AT perreaulttanya roleformir204inhumanpulmonaryarterialhypertension
AT melochejolyane roleformir204inhumanpulmonaryarterialhypertension
AT paquetericr roleformir204inhumanpulmonaryarterialhypertension
AT biardelsabrina roleformir204inhumanpulmonaryarterialhypertension
AT provenchersteeve roleformir204inhumanpulmonaryarterialhypertension
AT cotejacques roleformir204inhumanpulmonaryarterialhypertension
AT simardmartinj roleformir204inhumanpulmonaryarterialhypertension
AT bonnetsebastien roleformir204inhumanpulmonaryarterialhypertension